Novo Nordisk A/S (NONOF)
| Market Cap | 177.19B -13.9% |
| Revenue (ttm) | 50.70B +5.7% |
| Net Income | 17.20B +9.1% |
| EPS | 3.80 +9.2% |
| Shares Out | n/a |
| PE Ratio | 10.54 |
| Forward PE | 12.03 |
| Dividend | 1.81 (4.51%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 153,737 |
| Open | 38.90 |
| Previous Close | 40.31 |
| Day's Range | 38.90 - 40.50 |
| 52-Week Range | 34.00 - 64.75 |
| Beta | 0.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?
Novo got a much-needed boost from its latest earnings report.
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in clinical tria...
Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2
Novo Nordisk (NVO) announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once-weekly injection use v...
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at si...
Lexicon (LXRX) Q3 2026 Earnings Call Transcript
Novo Nordisk milestone payment shapes quarter as HCM readout nears.
Novo Nordisk price target raised to DKK 298 from DKK 296 at Citi
Citi raised the firm’s price target on Novo Nordisk (NVO) to DKK 298 from DKK 296 and keeps a Neutral rating on the shares.
Indian drugmaker Dr Reddy's gets Brazil regulator nod to sell generic Ozempic
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had received regulatory approval in Brazil to market and sell a generic version of Novo Nordisk's blockbuster diabetes drug Ozempic.
Novo Nordisk: 3 Key Takeaways for Long-Term Investors
U.S. pricing pressure weighs on Novo Nordisk's growth, but management is counting on the pipeline to offset it over the long haul.
Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know
The Wegovy maker raised its outlook again and the stock jumped. But its CEO refused to forecast next year, and handed investors six clues instead.
Novo Nordisk stock jumps as Wegovy pill sales beat estimates
Novo Nordisk shares NVO rallied on Wednesday after the Danish drugmaker reported stronger-than-expected third-quarter results, driven by demand for its Wegovy weight-loss pill, and raised its full-yea...
Novo Nordisk A/S Reports Q3 2026 Adjusted Operating Profit of DKK 31,720 million
Novo Nordisk A/S reported its financial results for the period 1 January 2026 to 30 September 2026. In Q3 2026, the company's adjusted sales increased by 4% at CER to DKK 79,195 million, driven by con...
Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript
Wegovy pill uptake and CagriSema trial results shape the growth recovery story.
Stocks making the biggest moves premarket: Trump Media, Tesla, CoreWeave, Novo Nordisk and more
These are the stocks posting the largest moves in the premarket.
Novo Nordisk beats Q3 profit forecast with 27% growth, raises 2026 outlook
Novo Nordisk's Q3 adjusted operating profit grew 27%, above expectations, and the Wegovy maker raised its 2026 sales and profit outlook range to between a 2% decline and 2% growth.
GLP-1 drugs help control prediabetes better than current standard medicine
Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.
Novo Nordisk Earnings Call Transcript: Q3 2026
Q3 adjusted sales rose 4% to DKK 79.2bn and adjusted operating profit rose 27%; FY 2026 adjusted growth guidance is -2% to +2% at CER. GLP-1 volume and launches supported recovery, while pricing, LOE and payer access remain key offsets.
Novo Nordisk Quarterly report: Q3 2026
Novo Nordisk has published its Q3 2026 quarterly earnings report on November 4, 2026.
Novo Nordisk Slides: Q3 2026
Novo Nordisk has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
2 Reasons for Hope From Novo Nordisk Earnings
The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
Novo Nordisk Raises Full-Year Outlook As GLP-1 Portfolio Continues To Drive Growth
(RTTNews) - Novo Nordisk (NVO) reported stronger-than-expected third-quarter results and raised its full-year outlook, supported by continued demand for its GLP-1 medicines used to treat obesity and d...
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
Novo Reports Q3 Beat, Raises 2026 Sales Forecast on Obesity Demand; NVO Stock Jumps 5%
Novo shares ($NVO) climbed more than 5% to about $42 in Wednesday’s pre-market session after the Danish pharma giant reported third-quarter 2026 earnings that beat expectations on sales and profits.
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
Novo Nordisk Q3 Adj. Operating Profit Increases, Obesity Sales Up 22%; Raises 2026 Outlook
(RTTNews) - Novo Nordisk A/S (NVO, NOVOB.CO, NOV.DE) reported third quarter net profit of 16.74 billion Danish kroner, a decline of 16% year-over-year. Earnings per share/ ADR was 3.79 kroner, down 16...